NCT06845891Completed
Clinical Study: Analysis of Glycemic Control and Satisfaction With a Connected Smart Cap in Patients With Type 1 Diabetes Mellitus
Estudio clínico: Analisis de Control Glucemico y Satisfaccion Con un Cap Conectado en Pacientes Con dm Tipo 1
Source: ClinicalTrials.gov · Last updated 17 Sept 2026
Brief summary (registry, in English)
This clinical study evaluates the impact of the Cap INSULCLOCK device on glycemic control, treatment adherence, and patient satisfaction in adults with type 1 diabetes mellitus (T1DM). Despite advances in pharmacology and technology, a significant proportion of individuals with T1DM fail to achieve recommended glycemic targets, partly due to the complexity of insulin therapy and suboptimal adherence. Cap INSULCLOCK is a device that attaches to insulin pens, automatically recording injections and integrating data on glucose levels, insulin administration, food intake, and physical activity, with real-time Bluetooth transmission. Its use may enhance adherence and optimize metabolic control. This study is a randomized, low-intervention clinical trial conducted at a single center, enrolling 42 patients, who will be randomized into two groups: one using the activated device and a control group using the device in a blinded mode. The primary objective is to assess differences in time above range (TAR \>180 mg/dL) over the last 14 days of continuous glucose monitoring (CGM). Secondary objectives include evaluating HbA1c levels, time in range (TIR), frequency of hypoglycemic episodes, and patient satisfaction. Data will be analyzed using advanced statistical methods, and the intervention is expected to improve adherence, reduce glycemic variability, and enhance quality of life in individuals with T1DM
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 42 (actual)
- First submitted
- 17 Feb 2025
- Start date
- 26 Feb 2025
- Primary completion date
- 19 Jun 2025
- Lead sponsor
- Fernando Sebastián Valles
- Diseases
- Type 1 diabetes
- NCT number
- NCT06845891
What you commit to
- Study type: Interventional
- Participants enrolled: 42
- From 26 Feb 2025 to the primary completion date, 19 Jun 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Severe acute illness.
Lab values
- Exclusion criteria for the use of real-time continuous glucose monitoring (RT-CGM) systems as per the Framework Agreement of the Community of Madrid for RT-CGM use (SERMAS).
Other
- Current pregnancy.
- Inability to provide informed consent or to meet the study requirements for any reason.
Who the study is looking for
- Men and women aged 18 years or older.
- Diagnosis of type 1 diabetes mellitus (T1DM).
- Users of flash continuous glucose monitoring (FGM) sensors with \>70% of recorded data, including intake and insulin dose logs.
- Adequate therapeutic adherence, with no missed appointments in the past year.
- Time above range (TAR \>180 mg/dL) \>25%.
- Ability to provide informed consent to participate in the study.
- Access to technology for follow-up, including a smartphone with internet connectivity and compatibility with the Insulcloud app.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital Universitario de la Princesa Coordinator of this site? Confirm its status | Madrid | Spain | Unknown status |
Related publications
This page is information, not medical advice. Discuss any trial with your doctor.